Cabaletta Bio

Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) announced plans to showcase updated clinical data on its investigational CD19-CAR T cell therapy, resecabtagene autoleucel (rese-cel), during two prominent scientific conferences this …

Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences Read More